ERIC K. ROWINSKY, M.D. - Corporate Board Profile

BIOGEN INC.

Filing Date	Source Excerpt
2014-04-30	Eric K. Rowinsky, M.D. Age: 57 Director since: 2010 Committee Memberships: Compensation and Management Development, Science and Technology
2015-04-30	Eric K. Rowinsky, M.D. Age: 58 Committee Memberships: Compensation and Management Development, Corporate Governance, Science and Technology Dr. Rowinsky has served as one of our directors since 2010.
2016-04-15	Dr. Rowinsky, 59, has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. From January 2012 to November 2015, Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center's Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky has extensive research and drug development experience, oncology expertise, and broad scientific and medical knowledge. Biogen Committee Memberships: Compensation and Management Development, Corporate Governance, Science and Technology. 2015 Director Compensation: $401,508.
2017-04-26	Dr. Rowinsky, 60, has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. Biogen Committee Memberships: Compensation and Management Development, Corporate Governance, Science and Technology. 2016 Director Compensation: $420,420.
2018-04-27	Dr. Rowinsky, 61, has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2016. Since June 2016, Dr. Rowinsky has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015, Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky serves as a director of Fortress Biotech Inc., a biopharmaceutical company, and Verastem, Inc., a biopharmaceutical company. Dr. Rowinsky has extensive research and drug development experience and broad scientific and medical knowledge. Biogen Committee Memberships: Compensation and Management Development, Corporate Governance, Science and Technology. 2017 Director Compensation: $418,979.
2019-04-30	Dr. Rowinsky has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2016. Since June 2016 Dr. Rowinsky has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones.
2020-04-20	Dr. Rowinsky has served as President of RGenix, Inc... Biogen Board Committee: Corporate Governance... 2019 Director Compensation: Eric K. Rowinsky total $411,143.
2021-04-23	Dr. Rowinsky is President and Executive Chairman of RGenix, Inc... Biogen Board Committee: Corporate Governance... 2020 Director Compensation: Eric K. Rowinsky total $409,314.
2022-04-29	Dr. Rowinsky has served as Chief Medical Officer of Hummingbird Biotherapeutics... Biogen Board Committee: Corporate Governance... 2021 Director Compensation: Eric K. Rowinsky Fees Earned or Paid in Cash $140,000, Stock Awards $270,413, Total $410,413.
2023-04-28	Eric K. Rowinsky, M.D. Director Since: 2010 Age: 66 Biogen Board Committee: Corporate Governance 2022 Director Compensation Table: Eric K. Rowinsky Fees Earned or Paid in Cash: $140,000 Stock Awards: $270,246 Total: $410,246